ORMP
Oramed Pharmaceuticals Inc.
There isn't enough reported data to score ORMP yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ORMP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Unavailable |
ORMP's profitability is currently strong. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ORMP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.2x | $4.03 | — |
| Cheap | 1.5x | $5.25 | +30% |
| Fair | 5.7x | $19.40 | +381% |
| Expensive | 85x | $290 | +7101% |
Historical ranges are pointers, not guarantees.
ORMP's PE is 1.2x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ORMP in the historical PE scenario, which offers more potential upside but is not a forecast.
ORMP Forward outlook
There aren't enough analyst estimates for ORMP to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ORMP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.43 | +246% |
| Q2 2026 | $4.13 | +$4.75 |
| Q1 2026 | $2.60 | +$3.31 |
| Q4 2025 | $1.50 | +$1.98 |
| Q3 2025 | $0.99 | +$1.03 |
| Q2 2025 | -$0.62 | -272% |
| Q1 2025 | -$0.71 | -745% |
| Q4 2024 | -$0.48 | -443% |
ORMP has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ORMP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $674K | 0% |
| Q1 2023 | $666K | 0% |
| Q4 2022 | $681K | -25% |
| Q3 2022 | $682K | -0.1% |
| Q2 2022 | $674K | -1% |
| Q1 2022 | $666K | +0.2% |
| Q4 2021 | $904K | +34% |
| Q4 2021 | $674K | 0% |
ORMP's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -225% | N/A |
| Q2 2023 | -562% | +1132 points |
| Q1 2023 | -782% | +908 points |
| Q4 2022 | -1430% | -67 points |
| Q3 2022 | -1201% | -4.9 points |
| Q2 2022 | -1694% | -609 points |
| Q1 2022 | -1689% | -791 points |
| Q4 2021 | -1364% | -632 points |
ORMP's operating margin was −225% last quarter, up 976 points from the same quarter a year ago, near the top of its range since 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ORMP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $422K | +$2M |
| Q2 2026 | -$202K | +$3.3M |
| Q1 2026 | -$2.9M | +$602K |
| Q4 2025 | -$468K | +$1.5M |
| Q3 2025 | -$1.6M | +$5.5M |
| Q2 2025 | -$3.5M | -270% |
| Q1 2025 | -$3.5M | -$2M |
| Q4 2024 | -$1.9M | -$501K |
ORMP has burned cash in almost every quarter: −$3M over the past year, against −$11M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ORMP on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORMP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +514K shares |
| 1 year | +0.6% | +241K shares |
| 3 years | +6.4% | +2.6M shares |
| 5 years | +17% | +6.3M shares |
| Available history | +141% | +25.2M shares |
ORMP has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $4M |
| Q3 2025 | $361,000 |
| Q4 2024 | $1.2M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ORMP Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ORMP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 8.9 | Oversold |
ORMP's weekly RSI is 47 (neutral) and its Stochastic is 9 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ORMP PE vs Healthcare Sector
| Metric | ORMP | Sector median | Relative |
|---|---|---|---|
| PE | 1.2x | 26x | 95% below |
| PE % | 10 | 29 | 19 pts below |
ORMP has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ORMP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.22 | 4.5% below |
| 20 week MA | $4.38 | 8% below |
| 50 week MA | $3.89 | 3.6% above |
| 100 week MA | $3.08 | 31% above |
| 200 week MA | $2.83 | 42% above |
ORMP has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 42% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ORMP on trend strength, trading above more of its moving averages.
ORMP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.18 | $4.54 | -12% |
| 2021 | $4.54 | $15.5 | +242% |
| 2022 | $15.5 | $11.0 | -29% |
| 2023 | $11.0 | $2.31 | -79% |
| 2024 | $2.31 | $2.37 | +2.6% |
| 2025 | $2.37 | $2.95 | +24% |
| 2026 YTD | $2.95 | $4.03 | +37% |
ORMP's yearly returns have swung widely, from +242% in 2021 to −79% in 2023. It's up 37% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ORMP on returns for 2026, with the stronger performance.